Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children

NCT05155579 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT05155579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05155579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children
Lead sponsor
University of Oxford
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2022
Completion date
May 27, 2025
Enrollment
594 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria